


CLAIMS

1. A compound according to the general formula:



or a pharmaceutically acceptable salt thereof, wherein:

R₁ is independently selected from: carboxylic acid (-CO₂H); phosphonic acid (-PO(OH)₂); phosphamic acid (-PO(OH)NH₂); sulphonic acid (-SO₂OH); hydroxamic acid (-CONHOH); oxamic acid (-NHCOCO₂H); and malonamic acid (-NHCOCH₂CO₂H), or any other possible bioisosteric equivalent of the groups above;

R₂ and R₃ are the same or different and independently selected from: chlorine; bromine; iodide; C₁₋₄ alkyl, said alkyl, or a bioisosteric equivalent optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different;

R₄ and R₆ are the same or different and independently selected from: hydrogen; halogen; C₁₋₄ alkyl; or a bioisosteric equivalent optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different;

R₅ is selected from: C₆₋₁₀ aryl; C₁₋₉ heteroaryl, said aryl; and heteroaryl optionally substituted with 0, 1, 2, or 3 groups of R^b which groups may be the same or different;

R^a represents fluorine or chlorine;

R^b represents a member selected from the group of: halogen; -CN; -CO₂H; -CHO; -NH₂; C₁₋₄ alkyl; C₂₋₄ alkenyl; C₂₋₄ alkynyl; C₁₋₄ alkoxy; C₂₋₄ alkenoxy; C₂₋₄ alkynoxy; C₁₋₄ alkylthio; C₂₋₄ alkenylthio; C₂₋₄ alkynylthio; C₆ aryl; C₁₋₅ heteroaryl; C₃₋₆ cycloalkyl; -NH(C₁₋₄); -N(C₁₋₄)₂; -NH(C₆ aryl); -N(C₆ aryl)₂; -NH(C₁₋₅ heteroaryl); and -N(C₁₋₅ heteroaryl)₂ or a bioisosteric equivalent;

n is an integer of 1, 2 or 3;

included for the variables above are all the possible stereoisomers thereof; prodrug ester forms thereof; and radioactive forms thereof.

2. A compound according to claim 1 wherein R₁ is carboxylic acid (-CO₂H).
3. A compound according to claim 1 or 2 wherein R₂ and R₃ is bromine or chlorine.
4. A compound according to any one of claims 1 to 3 wherein R₄ is isopropyl and R₆ is hydrogen.
5. A compound according to any one of claims 1, 2 or 4 wherein R₂ and R₃ is bromine.
6. A compound according to any one of claims 1 to 5 which is:
 - {4,6-Dibromo-5-[3-isopropyl-4-(naphthalen-2-yl-methoxy)phenoxy]indan-1-yl}-acetic acid;
 - {4,6-Dibromo-5-[4-(4-fluorobenzyloxy)-3-isopropylphenoxy]indan-1-yl}acetic acid;
 - {4,6-Dibromo-5-[3-isopropyl-4-(5-methylisoxazol-3-ylmethoxy)phenoxy]indan-1-yl}acetic acid;
 - {4,6-Dibromo-5-[3-isopropyl-4-(pyridin-2-yl-methoxy)phenoxy]indan-1-yl}acetic acid;
 - 4,6-Dibromo-5-[3-isopropyl-4-(5-phenyl-[1,2,4]oxadiazol-3-ylmethoxy)phenoxy]indan-1-yl}acetic acid;
 - 4-[4-(4,6-Dibromo-1-carboxymethyl-indan-5-yloxy)-2-isopropylphenoxy-methyl]-benzoic acid;
 - (4,6-Dibromo-5-4-[2-(1*H*-indol-2-yl)ethoxy]-3-isopropylphenoxy}indan-1-yl)acetic acid;
 - (4,6-Dibromo-5-[3-isopropyl-4-(5-thiophen-3-yl-[1,2,4]oxadiazol-3-yl-methoxy)-phenoxy]indan-1-yl}acetic acid;
 - {5-[4-(4-Amino-6-phenylamino[1,3,5]triazin-2-ylmethoxy)-3-isopropylphenoxy]-4,6-dibromoindan-1-yl}acetic acid;

{4,6-Dibromo-5-[3-isopropyl-4-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenoxy]-indan-1-yl}acetic acid;

{4,6-Dibromo-5-[4-(3,5-dimethylisoxazol-4-ylmethoxy)-3-isopropylphenoxy]-indan-1-yl}acetic acid;

and pharmaceutically acceptable salts thereof, and stereoisomers thereof.

7. A compound according to any one of claims 1 to 6, which have one or more asymmetric centers and can exist in the form of racemates, single and multiple enantiomers, as individual diastereomers, with all possible isomers, and mixtures thereof.
8. A compound according to any one of claims 1 to 7 for use in medical therapy.
9. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 7 or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.
10. A method for preventing, inhibiting or treating a disease which is dependent on the expression of a T₃ regulated gene or associated with metabolic dysfunction, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound according to any one of claims 1 to 7.
11. The method according to claim 10 wherein the disease is selected from cardiac arrhythmias, thyrotoxicosis, subclinical hyperthyroidis, certain skin disorders, and certain liver diseases.
12. The method according to claim 11 wherein the disease is a skin disorder or skin disease.
13. The method according to claim 12 wherein the skin disorder or skin disease is selected from: keloids, lichen planus, ichthyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis, and hirsutism.
14. The method according to claim 11 wherein the disease is a liver disorder or liver disease.

15. The method according to claim 14 wherein the liver disorder or liver disease is selected from: chronic alcoholism, acute hepatitis, chronic hepatitis, hepatitis C-induced liver cirrhosis, and liver fibrosis.
16. A method to treat certain skin disorders or diseases by the use of a compound according to any one of claims 1 to 7 in a combination with a retoid or a Vitamin D analog.
17. The use of a compound according to any one of claims 1 to 7 in the preparation of a medicament for the treatment of a disease or disorder which is dependent on the expression of a T₃ regulated gene.
18. The use according to claim 17 wherein the disease or disorder is cardiovascular disorder, thyrotoxicosis, subclinical hyperthyrodism, certain skin disorders and certain liver diseases.
19. The use according to claim 17 wherein the disease or disorder is selected from atrial fibrillation, ventricular tachycardia and ventricular fibrillation.
20. The use according to claim 17 wherein the disease or disorder is selected from thyrotoxicosis, subclinical hyperthyrodism and other related endocrine disorders, related to thyroid hormone.
21. The use according to claim 17 wherein the disease is a liver disorder or liver disease.
22. The use according to claim 21 wherein the liver disorder or liver disease is selected from: chronic alcoholism, acute hepatitis, chronic hepatitis, hepatitis C-induced liver cirrhosis, and liver fibrosis.
23. The use of a compound according to any one of claims 1 to 7 in the preparation of a medicament for the treatment of anoxic tissue damage.
24. The use of a labeled compound, according to any one of claims 1 to 7, as a diagnostic agent.